In vivo, FOXP4-AS1 overexpression resulted in reduced AKT phosphorylation levels during PTC tumor development, suggesting that FOXP4-AS1 inhibition of AKT activity is important for its tumor-suppressive role. Here, FOXP4 is linked to neoplasm.